Sanara MedTech Inc. (SMTI) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US79957L1008
Sanara MedTech Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 103.12 m USD |
| Gross profit | 95.60 m USD |
| Operating income | 7.30 m USD |
| EBIT | -30.81 m USD |
| Net income | -37.56 m USD |
| Diluted EPS – continuing operations | -4.36 USD |
Full history since 1999, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Sanara MedTech Inc.
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
More stocks
- Iochpe-Maxion S.A (MYPK3.SA)
- Socar Inc. (403550.KS)
- NewLake Capital Partners, Inc. (NLCP)
- Anhui Sentai WPC Group Share Co. Ltd. (301429.SZ)
- P.S.P. Specialties Public Company Limited (PSP.BK)
- Virginia National Bankshares Corp (VABK)
- Shanghai Shibei Hi-Tech Co Ltd B (900902.SS)
- Zhejiang Benli Technology Co. Ltd. (301065.SZ)
- Pentapro Materials Inc. (7887.TWO)
- Shanghai Kaytune Industrial Co.Ltd (301001.SZ)
- NORTHWEST BIOTHERAPEUTICS INC (NWBO)
- Hangzhou SDIC Microelectronics Inc. A (688130.SS)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.